Cerenome (PSTV) Share-based Compensation (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Share-based Compensation of $5.2 million for Q1 2026, up 3413.51% year-over-year from $148000.0 in Q1 2025, and up 779.74% quarter-over-quarter from -$765000.0 in Q4 2025.
Cerenome (PSTV) Share-based Compensation (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Share-based Compensation for 17 consecutive years, with $5.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 3413.51% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (up 467.69% YoY), while the FY2025 annual figure was $5.1 million, up 628.57% from the prior year.
- Share-based Compensation improved to $5.2 million in Q1 2026 per PSTV's latest filing, from -$765000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.4 million in Q3 2025 and bottomed at -$765000.0 in Q4 2025.
- Historically, Share-based Compensation has averaged $1.0 million across 5 years, with a median of $700000.0 in 2024.
- Annual changes were most pronounced in 2025 — Share-based Compensation slumped 697.66% — and 2026, when it jumped 3413.51%.
- Plus Therapeutics' Share-based Compensation stood at $130000.0 in 2022, then surged by 280.0% to $494000.0 in 2023, then tumbled by 74.09% to $128000.0 in 2024, then plunged by 697.66% to -$765000.0 in 2025, then surged by 779.74% to $5.2 million in 2026.
- Business Quant data shows PSTV's Share-based Compensation at $5.2 million in Q1 2026, -$765000.0 in Q4 2025, and $5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | - |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 4.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.20 Mn |
| Mar 31, 2026 | 5.20 Mn |
| Dec 31, 2025 | -765,000.00 |
| Dec 31, 2025 | -765,000.00 |
| Sep 30, 2025 | 5.40 Mn |
| Sep 30, 2025 | 5.40 Mn |
| Jun 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Mar 31, 2025 | 148,000.00 |
| Mar 31, 2025 | 148,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Dec 31, 2023 | 494,000.00 |
| Dec 31, 2023 | 494,000.00 |